Ingalls & Snyder LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

Ingalls & Snyder LLC’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,500	Closed	-$359K	–	471
2024 Q3	$359K	Sell	11,500 -10,188	-47%	-$318K	0.01%	341
2024 Q2	$580K	Sell	21,688 -1,000	-4%	-$29K	0.02%	276
2024 Q1	$774K	Hold	22,688	–	–	0.03%	244
2023 Q4	$657K	Sell	22,688 -2,000	-8%	-$53K	0.03%	251
2023 Q3	$681K	Sell	24,688 -11,400	-32%	-$347K	0.03%	246
2023 Q2	$1.08M	Sell	36,088 -100	-0.3%	-$3.5K	0.05%	202
2023 Q1	$1.31M	Sell	36,188 -4,000	-10%	-$154K	0.07%	176
2022 Q4	$1.43M	Hold	40,188	–	–	0.08%	162
2022 Q3	$1.36M	Hold	40,188	–	–	0.08%	162
2022 Q2	$1.16M	Hold	40,188	–	–	0.06%	182
2022 Q1	$1.3M	Hold	40,188	–	–	0.06%	190
2021 Q4	$1.17M	Sell	40,188 -29,800	-43%	-$904K	0.05%	209
2021 Q3	$1.87M	Sell	69,988 -2,300	-3%	-$61.7K	0.09%	168
2021 Q2	$2.23M	Hold	72,288	–	–	0.1%	156
2021 Q1	$1.89M	Hold	72,288	–	–	0.09%	166
2020 Q4	$1.82M	Buy	72,288 +900	+1%	+$19.4K	0.09%	162
2020 Q3	$1.49M	Buy	71,388 +200	+0.3%	+$4.54K	0.1%	144
2020 Q2	$1.69M	Buy	71,188 +500	+0.7%	+$11K	0.1%	151
2020 Q1	$1.27M	Hold	70,688	–	–	0.09%	168
2019 Q4	$1.68M	Sell	70,688 -104,200	-60%	-$2.53M	0.09%	151
2019 Q3	$4.81M	Buy	174,888 +9,800	+6%	+$290K	0.23%	92
2019 Q2	$5.46M	Sell	165,088 -5,500	-3%	-$188K	0.26%	84
2019 Q1	$5.98M	Sell	170,588 -500	-0.3%	-$18.6K	0.28%	83
2018 Q4	$5.68M	Sell	171,088 -100	-0.1%	-$4.3K	0.3%	81
2018 Q3	$8.62M	Hold	171,188	–	–	0.36%	69
2018 Q2	$10.2M	Sell	171,188 -2,347	-1%	-$122K	0.48%	60
2018 Q1	$7.95M	Sell	173,535 -2,000	-1%	-$83.5K	0.39%	66
2017 Q4	$7M	Sell	175,535 -100	-0.1%	-$3.95K	0.32%	70
2017 Q3	$7.03M	Hold	175,635	–	–	0.37%	61
2017 Q2	$7.57M	Sell	175,635 -5,000	-3%	-$178K	0.41%	56
2017 Q1	$5.65M	Sell	180,635 -10,000	-5%	-$268K	0.3%	68
2016 Q4	$4.81M	Sell	190,635 -2,000	-1%	-$44.7K	0.26%	75
2016 Q3	$4.76M	Hold	192,635	–	–	0.27%	74
2016 Q2	$3.92M	Hold	192,635	–	–	0.23%	85
2016 Q1	$2.94M	Buy	192,635 +9,500	+5%	+$124K	0.19%	96
2015 Q4	$2.46M	Buy	183,135 +14,188	+8%	+$219K	0.16%	100
2015 Q3	$2.37M	Hold	168,947	–	–	0.15%	100
2015 Q2	$2.87M	Hold	168,947	–	–	0.16%	101
2015 Q1	$2.04M	Buy	168,947 +53,847	+47%	+$509K	0.11%	126
2014 Q4	$955K	Buy	+115,100	New	+$967K	0.06%	177

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Ingalls & Snyder LLC's SUPN Position: Q4 2024 in Review

Ingalls & Snyder LLC sold out of Supernus Pharmaceuticals (SUPN) in Q4 2024, closing a stake of 11,500 shares — an estimated $359K sold.

Ingalls & Snyder LLC first reported a position in SUPN in Q4 2014 and held it in 40 quarters. The position peaked at $10.2M in Q2 2018. 294 funds tracked by Wall St. Rank hold SUPN as of Q4 2024.

Ingalls & Snyder LLC reported no remaining Supernus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Ingalls & Snyder LLC sold 11,500 Supernus Pharmaceuticals shares in Q4 2024, an estimated $359K.
Ingalls & Snyder LLC first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 40 quarters.
Ingalls & Snyder LLC's Supernus Pharmaceuticals position peaked at $10.2M in Q2 2018.
294 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2024.

Based on Ingalls & Snyder LLC's 13F filing for Q4 2024, filed 29 Jan 2025.